𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokine-activated killer cells plus interleukin-2

✍ Scribed by Deric D. Schoof; Yasunori Terashima; Steven Batter; Linda Douville; Jerome P. Richie; Timothy J. Eberlein

Book ID
119047185
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
720 KB
Volume
41
Category
Article
ISSN
0090-4295

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Metastatic renal-cell carcinoma patients
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon Ξ³: Immunological monitoring
✍ FranΓ§oisc Farace; Marc Pallardy; Eric Angevin; Thierry Hercend; Bernard Escudier πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 French βš– 737 KB

## Abstract We investigated the biological response of 73 patients with metastatic renal‐cell carcinoma (MRCC) treated by repetitive weekly cycles of high‐dose interleukin 2 (IL‐2) (protocol 1, 40 patients) or IL‐2 plus interferon‐gamma (IFN‐γ) (protocol 2, 33 patients). The objectives of this stud

Adoptive immunotherapy with lymphokine-a
Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma
✍ Saburo Onishi; Toshiji Saibara; Masanao Fujikawa; Hiroshi Sakaeda; Yasushi Matsu πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 591 KB

Ten patients with hepatocellular carcinoma, three of whom had pulmonary metastasis, were treated with adoptive immunotherapy using autologous lymphokineactivated killer cells plus recombinant interleukin 2. Patients received 16 pg per day of recombinant interleukin 2 consecutively (for 14 to 64 days